Top entities: Omeros Corporation, Pomerantz LLP, European Union — European Medicines Agency, Danielle Peyton.

What category does this event fall under?

Regulatory — classified as securities fraud investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 14, 2026. Coverage continues to evolve.

Regulatory securities fraud investigation

Pomerantz Investigates Omeros Corporation Fraud

Q: When did this event occur?

First reported Jul 01, 2026; last updated Jul 14, 2026.

Q: What is the market impact?

General. The market is negatively impacted by the news of a potential securities fraud at Omeros Corporation, leading to a significant drop in its stock price.

Q: What were the key actions taken?

Pomerantz LLP investigates claims Omeros Corporation · European Union — European Medicines Agency adopted negative opinion Omeros Corporation · Omeros Corporation issued press release

Analysis based on 19 articles · First reported Jul 01, 2026 · Last updated Jul 14, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the news of a potential securities fraud at Omeros Corporation, leading to a significant drop in its stock price. This event also highlights the regulatory risks faced by biotechnology companies, potentially affecting investor confidence in the sector.

Biotechnology Legal Services

Event Summary

Pomerantz LLP is investigating Omeros Corporation for securities fraud and other unlawful business practices. This investigation was triggered by a significant 19.12% drop in Omeros Corporation's stock price on June 26, 2026, after the European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab, a drug intended for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The law firm is advising affected investors to contact Danielle Peyton to join a potential class action lawsuit.

Key Actions

100 Pomerantz LLP investigates claims Omeros Corporation

90 European Union — European Medicines Agency adopted negative opinion Omeros Corporation

80 Omeros Corporation issued press release

Entities Involved

stock

Omeros Corporation

Omeros Corporation is facing a securities fraud investigation by Pomerantz LLP after its stock price fell significantly due to a negative opinion from the European Union — European Medicines Agency regarding its drug narsoplimab. This event negatively impacts the company's reputation and stock value.

Importance 100.0 Sentiment -70.0

priv

Pomerantz LLP

Pomerantz LLP is initiating an investigation into Omeros Corporation for potential securities fraud, which is a core part of their business and could lead to a class action lawsuit.

Importance 80.0 Sentiment 20.0

govactor

European Union — European Medicines Agency

The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Omeros Corporation's drug narsoplimab, directly causing the company's stock price drop and triggering the subsequent investigation.

Importance 60.0 Sentiment 0.0

per

Danielle Peyton

Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the class action against Omeros Corporation.

Importance 20.0 Sentiment 0.0

Relationships

Pomerantz LLP related ↔ Danielle Peyton

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard